The CPhI New Drug R&D and CMC Summit Forum (CPhI Forum for short) is a value-sharing platform that serves China’s pharmaceutical industry and focuses on pharmaceutical innovation. CPhI China has become an annual event for stakeholders in China’s pharmaceutical industry, and the CPhI “Senior Meeting” will bring together exclusive groups of people in pharmaceutical innovation to propose new ideas, stimulate new vitality and focus on new developments for pharmaceutical innovation. “.
To help Chinese pharmaceutical companies continue to innovate, the CPhI Sympathy Conference, themed “Stirring the Great Era and Navigating the New Decade”, invites Chinese pharmaceutical innovation leaders to discuss pharmaceutical innovation in the new era, focusing on the frontier, discussing strategies, sharing useful information and consolidating the foundation. In the new year, CPhI’s “Thinking Forum” will go hand in hand with the innovative development of China’s pharmaceutical industry.
In recent years, under the guidance of the national innovation-driven strategy, the pharmaceutical ecological environment has undergone tremendous changes, leading the development of China’s pharmaceutical industry into a new era of innovation. After experiencing the baptism of the COVID-19 epidemic, China’s pharmaceutical industry has won a decisive victory, using innovation as the driving force to successfully complete the “13th Five-Year Plan”. In 2020, my country approved 14 class I innovative drugs, setting a new record. There are nearly 20 overseas licensing transactions for local innovative drugs, which are gradually being standardized and the internationalization process is progressing steadily. China’s independent innovation has demonstrated its true strength to the world and reached new paces. Facing the changes in the competitive landscape and the increase in the innovation threshold, if we want to stand out in high-level competition, we can only seek new breakthroughs by continuously increasing our innovative technologies, deeply exploring the potential value, focusing on the clinical needs of patients and utilizing differentiated research and development from speakers from previous conference series (in no particular order).
